FDA-cleared profile

Sonio Suspect

Sonio · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Concurrent physician reading aid for specified abnormal fetal ultrasound findings; patient management must not rely solely on the analysis.

Clinical role
Concurrent detection and characterization aid
Images and patients
Ultrasound · Obstetric/Fetal
Key limitation
Keep in mind: Only the specified findings and supported views/gestational ranges are covered. This is a concurrent aid, not a comprehensive exclusion of fetal abnormality or a standalone management decision.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Concurrent physician reading aid for specified abnormal fetal ultrasound findings; patient management must not rely solely on the analysis.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Obstetric/Fetal Input: Fetal ultrasound images acquired at gestational age 11-41 weeks, with finding-specific trimester and view restrictions.
  • Who uses it?Intended users: Interpreting physicians, including maternal-fetal medicine specialists, OB/GYNs and radiologists.
  • What does the software produce?Output: Flags for great-vessel malposition; absent or unusually sized vessel in the three-vessel view; ventricular disequilibrium or absence; thoracic or abdominal situs inversus; absent single stomach bubble or abnormally large stomach; absent cavum septum pellucidum; and absent corpus callosum.
  • What is its most important limitation?Key limitation: Only the specified findings and supported views/gestational ranges are covered. This is a concurrent aid, not a comprehensive exclusion of fetal abnormality or a standalone management decision.

Clinical takeaway. Clinical role: Concurrent physician reading aid for specified abnormal fetal ultrasound findings; patient management must not rely solely on the analysis.

Evidence takeaway. Evidence from the reviewed source record: Bench comparison of integration and cloud configurations used the predicate protocol/dataset criteria. Integration average sensitivity was 92.5% and specificity 90.4%; this was not a new prospective clinical-outcome study.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Concurrent physician reading aid for specified abnormal fetal ultrasound findings; patient management must not rely solely on the analysis.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Concurrent detection and characterization aid
  • Exact FDA submission
  • Checked 2026-09-05
Required input
Fetal ultrasound images acquired at gestational age 11-41 weeks, with finding-specific trimester and view restrictions.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Flags for great-vessel malposition; absent or unusually sized vessel in the three-vessel view; ventricular disequilibrium or absence; thoracic or abdominal situs inversus; absent single stomach bubble or abnormally large stomach; absent cavum septum pellucidum; and absent corpus callosum.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Baseline ACR patient-population label retained; the imaging target is fetal anatomy, not adult organs.

Intended users
Interpreting physicians, including maternal-fetal medicine specialists, OB/GYNs and radiologists.
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Only the specified findings and supported views/gestational ranges are covered. This is a concurrent aid, not a comprehensive exclusion of fetal abnormality or a standalone management decision.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
Bench comparison of integration and cloud configurations used the predicate protocol/dataset criteria. Integration average sensitivity was 92.5% and specificity 90.4%; this was not a new prospective clinical-outcome study.
  • Exact FDA submission
  • Checked 2026-09-05

Public summary does not report a single test sample total. The averages should not be interpreted as per-abnormality performance.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Bench comparison of integration and cloud configurations used the predicate protocol/dataset criteria. Integration average sensitivity was 92.5% and specificity 90.4%; this was not a new prospective clinical-outcome study.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Public summary does not report a single test sample total. The averages should not be interpreted as per-abnormality performance.

Reported sensitivity
92.5% (95% CI 90.9%-93.9%)
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Average for the K261519 integration configuration in standalone bench testing of the specified fetal findings under predicate protocol/dataset criteria. Sample total is not stated in the summary; no prospective screening-population sensitivity is inferred.

Reported specificity
90.4% (95% CI 89.1%-91.7%)
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Average for the K261519 integration configuration in standalone bench testing of the specified fetal findings under predicate protocol/dataset criteria. Sample total is not stated in the summary; not a per-finding or real-world prevalence-adjusted estimate.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K261519 cloud-to-integration standalone performance comparison

  • DesignBench comparison using predicate protocol and dataset criteria after conversion to embedded C++
  • PopulationFetal ultrasound views for the specified abnormal findings within labeled gestational-age restrictions
  • Scopeexact submission
  • Tested versionSonio Suspect K261519 integration configuration compared with cloud configuration
  • IndependenceSponsor or vendor study

K261519

Algorithms, weights and thresholds were unchanged. Public summary provides average sensitivity/specificity and confidence intervals, but not a sample total or prospective clinical outcomes.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

Downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Fetal ultrasound images acquired at gestational age 11-41 weeks, with finding-specific trimester and view restrictions.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · Sonio Suspect: K261519 Special 510(k) summary

  2. Routing

    Source context, not route validation: The third-party manufacturer is responsible for user-interface integration and final system validation; the integrated configuration must meet minimum hardware requirements.

    Scope: Exact FDA submission. The summary does not provide a procurement-ready list of compatible machine models or complete hardware specifications.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · Sonio Suspect: K261519 Special 510(k) summary

  3. AI processing

    Source context, not route validation: K261519 adds a C++ integration configuration for third-party ultrasound systems to the existing Python web-based/cloud configuration, with the algorithm logic, weights and thresholds unchanged.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · Sonio Suspect: K261519 Special 510(k) summary

  4. Returned objects

    Source context, not route validation: Flags for great-vessel malposition; absent or unusually sized vessel in the three-vessel view; ventricular disequilibrium or absence; thoracic or abdominal situs inversus; absent single stomach bubble or abnormally large stomach; absent cavum septum pellucidum; and absent corpus callosum.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · Sonio Suspect: K261519 Special 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Flags for great-vessel malposition; absent or unusually sized vessel in the three-vessel view; ventricular disequilibrium or absence; thoracic or abdominal situs inversus; absent single stomach bubble or abnormally large stomach; absent cavum septum pellucidum; and absent corpus callosum.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · Sonio Suspect: K261519 Special 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
K261519 adds a C++ integration configuration for third-party ultrasound systems to the existing Python web-based/cloud configuration, with the algorithm logic, weights and thresholds unchanged.
  • Exact FDA submission
  • Checked 2026-09-05
Integration
The third-party manufacturer is responsible for user-interface integration and final system validation; the integrated configuration must meet minimum hardware requirements.
  • Exact FDA submission
  • Checked 2026-09-05

The summary does not provide a procurement-ready list of compatible machine models or complete hardware specifications.

Security
Sonio's security page states HIPAA and GDPR compliance, HDS-certified cloud providers, SOC 2 Type 2 compliance, encryption at rest and in transit, a web application firewall with intrusion detection, and isolated regional deployments. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Embedded integration

C++ configuration for third-party ultrasound systems, with OEM responsibility for UI integration and final validation.

exact submission · checked 2026-09-05

Integration rollout context

The dated vendor announcement describes real-world integration testing as the next phase after clearance.

exact submission · checked 2026-09-05
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K261519
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Obstetric/Fetal
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-06-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
21Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata contained no PubMed or trial records for this ID; this is not a claim that no literature exists. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, vendor documentation, fda decision summary, vendor announcement, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    No OEM integration license or site price is established by the reviewed announcement or summary.

  • Pricing model: Not verified - checked 2026-09-05 - Exact FDA submission

    OEM, per-device and per-examination commercial terms require a quote.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Sonio Suspect reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    OEM-specific operator training, escalation and competency materials were not established.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Completed real-world integration testing and ongoing clinical monitoring commitments were not verified.

8 sources - 3 history items

Source ledger

  1. Sonio Suspect: K261519 Special 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: purpose, clinicalUse, modality, anatomy, input, output, limitations, deployment, integration, reportedSensitivity, reportedSpecificity, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Sonio Suspect model card (K261519)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Sonio receives FDA clearance for Sonio Suspect Integration Configuration

    Sonio - Published 2026-06-24 - Accessed 2026-09-05

    Scope: deployment, implementationCapabilities, commercialAvailability

  8. Sonio Security and Medical Device Regulatory Info

    Sonio - Accessed 2026-10-25

    Scope: security

Research history

  1. K261519 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252148

Butterfly Gestational Age Tool

Butterfly Network, Inc.

Authorized purpose: Butterfly Gestational Age Tool estimates gestational age for a singleton intrauterine pregnancy presumed to be 16 to 37 weeks within the labeled Butterfly ultrasound workflow; qualified professionals must review the output.

Modality
Ultrasound
Anatomy
Obstetric/Fetal
Decision
2026-03-27
FDA-cleared K250959

BioticsAI

Bioticsai, Inc.

Authorized purpose: BioticsAI assists healthcare professionals during and after fetal ultrasound acquisition and interpretation by detecting views and anatomical structures and facilitating quality-criteria verification on DICOM images and frames; it is a concurrent reading aid for the labeled GE ultrasound and prenatal population.

Modality
Ultrasound
Anatomy
Obstetric/Fetal
Decision
2025-12-22
FDA-cleared K243614

Sonio Suspect

Sonio

Authorized purpose: Concurrent or post-exam fetal ultrasound aid that identifies and characterizes eight abnormal findings for interpreting-physician review; not the sole basis for management.

Modality
Ultrasound
Anatomy
Obstetric/Fetal
Decision
2025-02-21

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history